These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17263227)

  • 1. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible Cardiomyopathy After Epirubicin Administration.
    Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M
    Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
    Meinardi MT; van Veldhuisen DJ; Gietema JA; Dolsma WV; Boomsma F; van den Berg MP; Volkers C; Haaksma J; de Vries EG; Sleijfer DT; van der Graaf WT
    J Clin Oncol; 2001 May; 19(10):2746-53. PubMed ID: 11352968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin.
    Okamoto T; Ogata J; Minami K
    Anesth Analg; 2003 Jul; 97(1):19-20, table of contents. PubMed ID: 12818936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
    Akpek M; Ozdogru I; Sahin O; Inanc M; Dogan A; Yazici C; Berk V; Karaca H; Kalay N; Oguzhan A; Ergin A
    Eur J Heart Fail; 2015 Jan; 17(1):81-9. PubMed ID: 25410653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of differential gene expression related to epirubicin-induced cardiomyopathy in breast cancer patients.
    Peng J; Wang Z; Li Y; Lv D; Zhao X; Gao J; Teng H
    Hum Exp Toxicol; 2020 Apr; 39(4):393-401. PubMed ID: 31823667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
    Ciotti R; Ucci G; Belotti G; Facchi E; Cremonesi M; Gatti C; Baccheta G
    J Clin Oncol; 2001 Nov; 19(22):4269-70. PubMed ID: 11709572
    [No Abstract]   [Full Text] [Related]  

  • 8. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

  • 10. [Polychemotherapy versus monotherapy in metastatic breast carcinoma].
    Tanner J; Dunst J
    Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983
    [No Abstract]   [Full Text] [Related]  

  • 11. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
    Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
    J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
    Lee YR; Kang MH; Park HM
    Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy during pregnancy: what is really safe?
    Peccatori F; Martinelli G; Gentilini O; Goldhirsch A
    Lancet Oncol; 2004 Jul; 5(7):398. PubMed ID: 15231245
    [No Abstract]   [Full Text] [Related]  

  • 14. Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer.
    Appel JM; Sogaard P; Mortensen CE; Skagen K; Nielsen DL
    J Am Soc Echocardiogr; 2011 Feb; 24(2):200-6. PubMed ID: 21227647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin for adjuvant therapy in node-positive breast cancer.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
    [No Abstract]   [Full Text] [Related]  

  • 17. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
    Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
    Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
    Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
    J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.